CLINICIANS

CLINICAL APPLICATIONS & FURTHER READING

Revita  , scientific and clinical evidence

®

Revita Logo full colour.jpg

Revita is an intact human placental membrane allograft that preserves all layers of the biologic tissue and maintains the physiologic 3D architecture of the natural barrier membrane.

tweezers.PNG

Intact Human Placental Membrane vs. Dehydrated Competitor

Revita preserves all three layers of the amniotic membrane architecture.

Unprocessed placental membrane

Unprocessed.png
Revita Logo full colour.jpg

Revita preservation of 3D architecture

Revita preserved.png

Competitor

Competitor.png

Revita provides the complete intact human placental membrane that is the physiologic tissue carrier naturally found in the body.

 

This complete membrane containing amnion, intermediate layer and chorion retains many of the cytokines and growth factors the body uses to heal, protect and grow tissues.

CLINICAL APPLICATIONS INCLUDE:

Wound Care             

  • Diabetic Wounds

  • Venous / Arterial Ulcers

  • Pressure Ulcers

  • Burn Wounds

  • Plastic Surgery

PRESERVATION OF THE INTERMEDIATE LAYER

The amniotic intermediate layer is a vital part of the membrane barrier present between the amnion and chorion layers

THE INTERMEDIATE LAYER:

  • Acts as a cushion

  • Contains Hyaluronic Acid (HA) + Collagen

  • Contains growth factors

  • Contains Glycosaminoglycans and Proteoglycans

CASE STUDY - Revita   Clinical Application: Challenging Chronic Wound

®

Day 0 Wound

Challenging Chronic Wound[1].png

Day 0 Application

Challenging Chronic Wound[1].png

Day 41

Challenging Chronic Wound[1].png

95% Closure

Challenging Chronic Wound[1].png

Introduction

The patient in this case study was selected to evaluate this exceptional product capacity in a notably challenging clinical application. The patient, an elderly woman with multiple comorbidities and existing amputations, presented with a deep venous leg ulcer that consistently failed other treatments. Her case is presented here.

Initial Patient Evaluation and Product Application: Day 0 

87-year-old female presented with a severe venous leg ulcer (VLU) on her lower right leg measuring 11 cm in length and 4 cm in width with exposed tendon and heavy exudate of purulent consistency. Conservative therapies were previously attempted for months without success.

 

The patient had a history of diabetes and smoking, and all toes had previously been amputated. She also reported a high pain level of 8 on a Visual Analog Scale (VAS) of 1 to 10 at the site of the VLU.

 

At the time of initial evaluation, the wound was cleaned and five Revita allografts were used to cover the wound.

Standard facility protocol for tissue application was followed, including placement of a non-adherent hydrogel for protection. Clinicians rated the ease of Revita application as excellent.

Follow Up: Day 27 

The wound was cleaned, debrided, and clinicians re-applied five Revita allografts. Clinicians rated the ease of Revita  application as excellent. 

Follow Up: Day 41 

Clinicians noted “good results” with healthy tissue developing around the previously exposed tendon. The wound was cleaned, debrided, and clinicians re-applied four Revita allografts. 


Final Treatment: Day 62 

Clinicians noted a “considerable improvement” with low exudate levels and healthy tissue development and reapplied three Revita allografts to continue treatment. 


Wound Resolution 

Wound continued to progress through to closure with “incredible results” noted by the clinicians.

Further Readings

REVITA SCIENTIFIC AND CLINICAL COMPENDIUM

- Stimlabs LLC

BIBLIOGRAPHY OF AMNIOTIC MEMBRANE TECHNOLOGY_2016 - Stimlabs LLC

REVITA A DERMATOLOGICAL EXCISION DEFECT CASE REPORT - Dr Callaway

CLINICAL LITERATURE REVIEW - Tony Parker, PhD 

THE USE OF A REVITA ALLOGRAFT FOR WOUND BED PREPARATION IN A TRAUMA INDUCED WOUND - Dr Sharif

StimLabs_Unprocessed_edited_edited.png

StimLabs Blog

Click on the button below to visit the StimLabs Blog 'StimLabs: Unprocessed' to keep up-to-date with information and advances from the USA

Our new Brisbane based advanced manufacturing facility is licensed by the TGA to manufacture Revita for clinical use in Australia.

(Licence # MI-2018-LI-13190-1)

Revita is registered on the Australian Register of Therapeutic Goods (ARTG Entry # 350670)

®

Register your interest in being notified when Revita  is available to order.

Register your interest here

Thanks for submitting!

Have questions or complaints about quality or regulatory compliance? Please contact us here

 
Register your question or complaint here

Thanks for submitting we will be in contact with you very soon!

Want more information?